AUSTIN, Texas, March 6, 2014 (GLOBE NEWSWIRE) -- LDR Holding Corporation (Nasdaq:LDRH), a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders, announced today that there have been more than 50,000 implantations of its exclusive VerteBRIDGE® plating technology worldwide. Since its introduction in 2007 in France and in 2008 in the United States, VerteBRIDGE technology has grown to a comprehensive platform of products with integrated, zero-profile, in-line plating technology adapted for use in anterior cervical, anterior lumbar, oblique lumbar, and lateral lumbar applications. LDR has experienced substantial and consistent growth with the ROI-C® cervical cage and the ROI-A® midline and oblique ALIF cages, and has seen early and significant adoption of the Avenue® L lateral lumbar cage. The portfolio of cages with VerteBRIDGE technology has been used by surgeons around the world and continues to show great potential.
William L. Mills, M.D., a board-certified orthopedic surgeon specializing in spinal procedures at Coastal Orthopedics in Conway, South Carolina, shares, "VerteBRIDGE plating technology gives me the unique ability to secure the primary stability of the interbody implant through a minimally invasive approach, in a trajectory that is directly in-line to the disc, and with an ease of use and reproducibility not elsewhere available in the market. For properly indicated patients, I feel that the stand-alone ability of ROI-C and ROI-A benefits those patients who can be treated without additional fixation."
The ROI-A, ROI-C and Avenue L cages all feature the ability to add zero-profile VerteBRIDGE plating. With its self-guided, curved plating delivered in the plane of the disc through a direct, mini-open approach, the technology requires less exposure than other integrated fixation systems secured with screws that must be inserted at oblique angles. The zero-profile, stand-alone construct of ROI-A with VerteBRIDGE has been well received by surgeon customers as it does not require protruding hardware on the anterior lumbar spine. In the cervical spine, the ROI-C cage with novel plating provides a stand-alone fusion solution that minimizes retraction and reduces the need for anterior plates and hardware that may contribute to dysphagia, or difficulty swallowing. VerteBRIDGE technology in the Avenue L lateral lumbar cage is especially attractive to surgeons who appreciate the ability to add integrated cage fixation without additional retraction of the psoas muscle.
Christophe Lavigne, CEO of LDR, comments, "Having reached more than 50,000 implantations of cages with VerteBRIDGE plating technology marks a significant milestone for LDR. VerteBRIDGE plating technology has established LDR as a market leader in the high-growth integrated fixation interbody fusion market, and represents the company's passion for innovation. We are pleased to bring what we believe to be important clinical and surgical benefits of VerteBRIDGE to more surgeons and patients worldwide. We are committed to the further development of our technology and expansion into new applications, which we believe will allow our surgeon customers to treat existing pathology differently."
About LDR Holding Corporation
LDR Holding Corporation is a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders. LDR's primary products are based on its exclusive VerteBRIDGE® fusion and Mobi® non-fusion technology platforms and are designed for applications in the cervical and lumbar spine. These technologies enable products that are less invasive, provide greater intra-operative flexibility, offer simplified surgical techniques and promote improved clinical outcomes for patients as compared to existing alternatives. LDR recently received approval from the U.S. Food and Drug Administration (FDA) for the Mobi-C® cervical disc replacement device, the first and only cervical disc replacement device to receive FDA approval to treat both one-level and two-level cervical disc disease. For more information regarding LDR, visit www.ldr.com or www.cervicaldisc.com.
This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief or current expectations of LDR and members of its management team with respect to LDR's future business operations as well as the assumptions upon which such statements are based. Forward-looking statements include specifically, but are not limited to, LDR's market opportunities, growth, future products, market acceptance of its products and sales and such statements are subject to risks and uncertainties such as the timing and success of new product introductions, physician acceptance, endorsement, and use of LDR's products, regulatory matters, competitor activities, changes in and adoption of reimbursement rates, potential product recalls, effects of global economic conditions and changes in foreign currency exchange rates. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found in LDR's Risk Factors disclosure in its Annual Report on Form 10-K, filed on March 4, 2014, and in LDR's other filings with the SEC. LDR disclaims any responsibility to update any forward-looking statements.
©2014 LDR Holding Corporation, All Rights Reserved
CONTACT: Jon Stone 646-747-7161 email@example.comSource:LDR Holding Corporation